Showing 1765 results
-
Press release /Crizanlizumab is a monthly infusion under development to prevent pain crises (also called vaso-occlusive crises, or VOCs) in patients with sickle cell disease Sickle cell VOCs, which are…
-
Press release /Sandoz is seeking approval for their proposed biosimilars adalimumab and infliximab for use in all indications of their respective reference medicines, Humira®* and Remicade®** Comprehensive data…
-
Press release /Filing acceptance marks second Priority Review granted to Kymriah by the FDA for two distinct indications, underscoring the potential of first ever FDA-approved CAR-T therapy EMA granted…
-
Press release /33 abstracts from the leading MS portfolio include data for Gilenya® (fingolimod), and investigational drugs siponimod (BAF312) and ofatumumab (OMB157) New research will be presented on…
-
Press release /Nearly all children with two and three copies of the SMN2 gene treated presymptomatically achieved age-appropriate milestones, including sitting, standing and walking. All children were free of…
-
Press release /Committee votes unanimously in favor of the Sandoz proposed biosimilar etanercept for all approved indications of the reference product …
-
Press release /REACH3 data show Jakavi significantly improved overall response rate (ORR) at week 24 (49.7% vs. 25.6%) with a higher best overall response rate (76.4% vs. 60.4%) vs. best available therapy, among…
-
Press release /Despite nearly 20 years of availability, biosimilars show worldwide adoption rate of only 14% in initiative-tracked countries, while reference medicines still represent 86% of biologic…
-
Press release /Sandoz is seeking approval of high concentration formulation (HCF) adalimumab for use in all indications of reference medicine Upon approval, HCF formulation will offer patients enhanced yet familiar…
-
Press release /In the largest and longest-running prospective trial in advanced SM, 60% of patients achieved complete or partial resolution of organ damage[1] Advanced SM is rare and has a poor prognosis[…